Skip to content

Lobbying by Pfizer Canada ULC: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Corporation

Pfizer Canada ULC

Meetings this Parliament
35
With MPs
12
Since Nov 2021
114
Active registrations
1

Most recent reported meeting: Aug 6, 2026.

Who they meet

Since the current Parliament opened.

MPs

Institutions

  • Innovation, Science and Economic Development Canada (ISED)13
  • Health Canada (HC)11
  • House of Commons8
  • Global Affairs Canada (GAC)6
  • Finance Canada (FIN)5
  • Treasury Board Of Canada Secretariat (TBS)4
  • Intergovernmental Affairs Secretariat (IGA)4
  • Public Services and Procurement Canada (PSPC)3

Registrations in effect

In-house (corporation) In effect since Jul 13, 2026

Filed by An Van Gerven, President

Lobbyists

  • An Van Gerven · President
  • Steven Hogue · Director, Global Policy and Public Affairs (Canada) Former public office holder

    Formerly Deputy Director of Communications, Communications, Office of the Prime Minister of Canada (2002–2003)

    Formerly Special Assistant (Quebec Issues), Operations, Office of the Prime Minister of Canada (2001–2002)

    Formerly Special Assistant (Quebec and Atlantic Issues), Minister's Office, Department of Fisheries & Oceans (1999–2001)

    Formerly Special Assistant (Quebec and Atlantic Issues), Minister's Office, Canada Customs and Revenue Agency (1998–1999)

Institutions they may lobby: Atlantic Canada Opportunities Agency (ACOA), Canada Border Services Agency (CBSA), Canada Economic Development for Quebec Regions, Canada Revenue Agency (CRA), Canadian Institutes of Health Research (CIHR), Employment and Social Development Canada (ESDC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Justice Canada (JC), National Defence (DND), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)

What they're lobbying on (22)
  • Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB).
  • Free trade agreements as they relate to the biopharmaceutical industry.
  • Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.
  • Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.
  • Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals.
  • Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policy
  • Monitoring and engaging on the Government’s national strategy for rare diseases; the Canadian Drug Agency; and the implementation of C64, An Act to Implement pharmacare.
  • Patented Medicine Prices Review Board (PMPRB) amendments to the Patented Medicines Regulations and the related new guidelines.
  • Advocacy on the Regulations Amending the Patent Rules and Certain Regulations Made Under the Patent Act which were published for consultation in Canada Gazette Part I (CGI) on May 18, 2024.1 Share concerns with Canada’s implementation of a patent term adjustment (PTA) system that is not compliant with its trade obligations, as it does not provide a meaningful remedy to patentees who are impacted by unreasonable patent office delays.
  • Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement
  • Advocacy on the role of the Health Emergency Readiness Canada (HERC) Agency
  • Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods
  • The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.
  • Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Drug Agency as well as the review times and processes conducted by Health Canada for the purpose of obtaining a notice of compliance.
  • Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy
  • Health Canada’s policies, program and guidelines related to the management, prevention, mitigation and notification of drug shortages
  • Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries
  • Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.
  • Discussions on the procurement of a COVID19 vaccine and therapy
  • Discussions around the World Trade Organization consideration of a TRIPS Patent Waiver and the World Health Organization pandemic treaty proposal
  • Consider amendments to the Food and Drugs Act, or the Export and Imports Permits Act (Export Control List) or any other legislative and regulatory means in order to protect the Canadian supply of drugs in light of potential importation legislation in the United States.
  • Advocacy to maintain and increase funding for the National Immunization Strategy and discussions on vaccine procurement.

Registration 960525-15283-47. Look it up in the official Registry

Reported meetings

Spreadsheet

Filed by Najah Sampson (55), An Van Gerven (36), Cole C. Pinnow (23).

  • Reported by An Van Gerven · In-house (corporation)

    • Shelby Kramp-Neuman · Member of Parliament
    • Randy Hoback · Member of Parliament
    • Holly Duggan · Director of Stakeholder Relations, House of Commons
    • Darren Hall · Policy Advisor, House of Commons
    Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Drug Agency as well as the review times and processes conducted by Health Canada for the purpose of obtaining a notice of compliance. Read more

    Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.

    Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement

    Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods

    Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy

    The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Wilder Walker-Stewart · Director of Policy, Public Services and Procurement Canada (PSPC)
    • Yianni Papadatos · Director of Parliamentary Affairs, Public Services and Procurement Canada (PSPC)
    • Kabisan Thanendran · Policy Advisor, Public Services and Procurement Canada (PSPC)
    Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods Read more

    Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement

    Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy

    The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.

    Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Drug Agency as well as the review times and processes conducted by Health Canada for the purpose of obtaining a notice of compliance.

    Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
    • Ali Ehsassi · Member of Parliament
    • Brandan Rowe · Chief of Staff to the Minister, Intergovernmental Affairs Secretariat (IGA)
    • Eve Loignon-Giroux · Senior Communications Advisor, Intergovernmental Affairs Secretariat (IGA)
    and 2 more
    • Rob Stewart · Deputy Minister, International Trade, Global Affairs Canada (GAC)
    • Martin Moen · Associate Assistant Deputy Minister of the International Trade Branch, Global Affairs Canada (GAC)
    Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods Read more

    Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement

    Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy

    Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Drug Agency as well as the review times and processes conducted by Health Canada for the purpose of obtaining a notice of compliance.

    Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.

    The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Sandenga Yeba · Deputy Chief of Staff & Director of Policy, Health Canada (HC)
    • Justine Frame · Special Assistant - Policy, Health Canada (HC)
    • Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
    • Bryn Savage · Policy Advisor, Health Canada (HC)
    Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Drug Agency as well as the review times and processes conducted by Health Canada for the purpose of obtaining a notice of compliance. Read more

    Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.

    Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement

    Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods

    Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy

    The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Elliott Lockington · Chief of Staff to the Minister, Treasury Board Of Canada Secretariat (TBS)
    • Elizabeth Wong · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods Read more

    Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement

    Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy

    Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Drug Agency as well as the review times and processes conducted by Health Canada for the purpose of obtaining a notice of compliance.

    The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Jocelyne Voisin · Assistant Deputy Minister, Health Canada (HC)
    Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement Read more

    Monitoring and engaging on the Government’s national strategy for rare diseases; the Canadian Drug Agency; and the implementation of C64, An Act to Implement pharmacare.

    Advocacy to maintain and increase funding for the National Immunization Strategy and discussions on vaccine procurement.

    Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Mary Robinson · Senator, Senate of Canada
    Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Drug Agency as well as the review times and processes conducted by Health Canada for the purpose of obtaining a notice of compliance. Read more

    Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy

    Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods

    Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement

    Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods Read more

    Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Manuela Tomic · Senior Advisor, Innovation, Science and Economic Development Canada (ISED)
    • Lisa Xie · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    Contribution to the Government Public consultations on Canada-United States-Mexico Agreement to inform Canada’s priorities in preparation for the first joint review of CUSMA by Canada, the United States and Mexico in 2026 and ahead of Canada’s chairing of the 5th meeting of the CUSMA Free Trade Commission, in 2025. Read more

    Advocacy on the creation of the Health Emergency Readiness Canada (HERC) Agency

    Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy

    Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods

    The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.

    Advocacy on the proposed Regulations Amending the Patent Rules and Certain Regulations Made Under the Patent Act which were published for consultation in Canada Gazette Part I (CGI) on May 18, 2024.1 Share concerns with Canada’s implementation of a patent term adjustment (PTA) system that is not compliant with its trade obligations, as it does not provide a meaningful remedy to patentees who are impacted by unreasonable patent office delays.

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy Read more

    Contribution to the Government Public consultations on Canada-United States-Mexico Agreement to inform Canada’s priorities in preparation for the first joint review of CUSMA by Canada, the United States and Mexico in 2026 and ahead of Canada’s chairing of the 5th meeting of the CUSMA Free Trade Commission, in 2025.

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Samuel Millar · Assistant Deputy Minister, Finance Canada (FIN)
    Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods

    Official report

  • Reported by Najah Sampson · In-house (corporation)

    • Ritu Banerjee · Associate Deputy Minister, Innovation, Science and Economic Development Canada (ISED)

    Foreign AffairsHealthIndustryInternational TradeResearch and DevelopmentScience and TechnologySmall BusinessTaxation and Finance

    Official report

  • Reported by Najah Sampson · In-house (corporation)

    • Carlos Pena Vallecillo · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)

    HealthIndustry

    Official report

  • Reported by Najah Sampson · In-house (corporation)

    • Luis Medina · Director of Parliamentary Affairs, Senate of Canada

    Federal-Provincial RelationsHealthIndustryResearch and Development

    Official report

  • Reported by Najah Sampson · In-house (corporation)

    Constitutional IssuesConsumer IssuesFederal-Provincial RelationsHealthIntellectual PropertyInternational TradeResearch and DevelopmentScience and TechnologyTaxation and Finance

    Official report

  • Reported by Najah Sampson · In-house (corporation)

    • Ritu Banerjee · Associate Deputy Minister, Innovation, Science and Economic Development Canada (ISED)

    Consumer IssuesFederal-Provincial RelationsForeign AffairsHealthIndustryIntellectual PropertyInternational TradeResearch and DevelopmentScience and TechnologySmall BusinessTaxation and Finance

    Official report

  • Reported by Najah Sampson · In-house (corporation)

    • Mary Ng · Minister of International Trade, Global Affairs Canada (GAC)
    • Kevin Coon · Chief of Staff, Global Affairs Canada (GAC)

    Intellectual PropertyInternational Trade

    Official report

  • Reported by Najah Sampson · In-house (corporation)

    • Blaine Calkins · Member of Parliament
    • Tom Kmiec · Member of Parliament
    • Earl Dreeshen · Member of Parliament, House of Commons
    • Stephen Ellis · Member of Parliament, House of Commons

    Federal-Provincial RelationsHealthIndustryIntellectual PropertyInternational TradeResearch and DevelopmentScience and TechnologyTaxation and Finance

    Official report

  • Reported by Najah Sampson · In-house (corporation)

    • Justin Trudeau · Prime Minister of Canada, Prime Minister's Office (PMO)
    • Kirsten Hillman · Ambassador of Canada to the United States, Global Affairs Canada (GAC)

    HealthIndustryInternational Trade

    Official report

  • Reported by Najah Sampson · In-house (corporation)

    • Brian Clow · Deputy Chief of Staff, Prime Minister's Office (PMO)
    • Jason Easton · Strategic Advisor Special Projects, Prime Minister's Office (PMO)
    • Sean Mullin · Special Advisor, Prime Minister's Office (PMO)
    • Elise Wagner · Director of Policy, Prime Minister's Office (PMO)
    and 1 more
    • Patrick Travers · Senior Global Affairs Advisor, Prime Minister's Office (PMO)

    International RelationsInternational Trade

    Official report

  • Reported by Najah Sampson · In-house (corporation)

    International RelationsInternational Trade

    Official report

  • Reported by Najah Sampson · In-house (corporation)

    • Kirsten Hillman · Ambassador of Canada to the United States, Global Affairs Canada (GAC)
    • Jerome Belanger · Chief of Staff to the Canadian Ambassador to the USA, Global Affairs Canada (GAC)
    • Jerome Belanger · Chief of Staff to the Canadian Ambassador to the USA, Global Affairs Canada (GAC)
    • Larissa Galadza · Head, Canada-US Engagement Task Force, Global Affairs Canada (GAC)

    International RelationsInternational Trade

    Official report

  • Reported by Najah Sampson · In-house (corporation)

    • Peter M. Boehm · Senator, Senate of Canada

    International Relations

    Official report

  • Reported by Najah Sampson · In-house (corporation)

    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)

    IndustryInternational Trade

    Official report

  • Reported by Najah Sampson · In-house (corporation)

    • François-Philippe Champagne · Minister, Innovation, Science and Economic Development Canada (ISED)
    • Mary Ng · Minister of Export Promotion, International Trade and Economic Development, Global Affairs Canada (GAC)

    IndustryInternational RelationsInternational Trade

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.